Cross-Reactive Profile Against Two Conserved Coronavirus Antigens in Sera from SARS-CoV-2 Hybrid and Vaccinated Immune Donors
- 3 February 2023
- journal article
- research article
- Published by Mary Ann Liebert Inc in Viral Immunology
- Vol. 36 (3), 222-228
- https://doi.org/10.1089/vim.2022.0186
Abstract
Since the beginning of the pandemic, the pre-existing immunity against SARS-CoV-2 has been postulated as one possible cause of asymptomatic infections. Later, various works reported that pre-existing immune response against the two structural conserved antigens: S2 subunit and the nucleocapsid protein, were associated to some level of asymptomatic profile in infected individuals. To explore the Ab background against these two antigens, in the context of vaccine-elicited and hybrid (natural infection plus vaccination induced) immunity of SARS-CoV-2, in this work, we tested sera from inactivated vaccine-immunized donors and from vaccinated and subsequent natural infected donors upon the Omicron variant wave in Guangdong province, China. Serum samples were collected from 27 COVID-19 convalescent, 25 SARS-CoV-2 vaccinated, and 10 negative donors. The IgG cross-reactivity response against these two antigens from another relevant human coronavirus (HCoV) was also evaluated. The findings indicate that IgG response against S2 and N protein was particularly higher in sera with hybrid immunity. The cross-reactive Abs were more significant against SARS-CoV-1, while a wide cross-reactivity was detected for N antigen for one human Alpha coronavirus HCoV-229E even in the negative control samples. The presence of cross-reactive Abs against the two conserved antigens N and S2, particularly in the context of hybrid immunity, could pave the way for future boosted vaccines carrying these conserved regions.Keywords
This publication has 26 references indexed in Scilit:
- Preexisting and de novo humoral immunity to SARS-CoV-2 in humansScience, 2020
- Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 InfectionFrontiers in Immunology, 2020
- Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19Cell, 2020
- SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognitionNature Immunology, 2020
- SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controlsNature, 2020
- Pre-existing immunity to SARS-CoV-2: the knowns and unknownsNature Reviews Immunology, 2020
- Development of an inactivated vaccine candidate for SARS-CoV-2Science, 2020
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed IndividualsCell, 2020
- Comparative computational analysis of SARS-CoV-2 nucleocapsid protein epitopes in taxonomically related coronavirusesMicrobes and Infection, 2020
- First infection by all four non-severe acute respiratory syndrome human coronaviruses takes place during childhoodBMC Infectious Diseases, 2013